Pyxis Oncology Inc. announced positive preliminary Phase 1 clinical trial data for Micvotabart Pelidotin (MICVO) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The results showed a 46% confirmed objective response rate $(ORR)$ and a 92% disease control rate (DCR) with MICVO as monotherapy in second-line or later (2L+) R/M HNSCC at 5.4 mg/kg. In combination with KEYTRUDA® (pembrolizumab), MICVO demonstrated a 71% confirmed ORR and 100% DCR in first-line and second-line or later (1L/2L+) R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg. These preliminary results were presented during a live conference call and webcast hosted by the company. Updated data from the ongoing Phase 1 monotherapy study are expected in mid-2026, while further updates from the Phase 1/2 combination study are anticipated in the second half of 2026.